Rahul G Argula

Husband, Dad, Crossword nerd, Classic Rock devotee, Politics junkie, Pulmonary/Critical care doc, Physiology buff, passionate about Pulmonary vascular disease.

[Rahul G Argula @RahulArgula]

@yreddyhf Agree. Great work! These patients (in our clinical practice) with low PVR are very fatigued, more SOB despite a low PVR. I also think this is an endophenotype within the SSc PAH population (due to high telangiectasia burden?). Paying close attention to the SVR is so important.

[Yogesh Reddy @yreddyhf]

As we enter the sotatercept era and move beyond vasodilators alone for PAH, we find that roughly 10% get high output states from vasodilators that is missed on non-invasive testing and worsens RV work due to volume load despite marked PVR reduction.

https://t.co/wNFEBJsW6d

[Rahul G Argula @RahulArgula]

@Anjaliydv1706 @yreddyhf @RyanTedfordMD @kurt_prins @sese_denise @AndrewJSauer @robmentz @MUSCCardFellows @ACCinTouch @hvanspall @VishalNRao It’s phase II. Phase III is underway. The journey in HFpEF is going to be more tricky as it is a different animal vs. PAH. For example, the concomitant atrial fibrillation and associated anticoagulant use will not be easy to navigate with the side effect profile of sotatercept.

[Rahul G Argula @RahulArgula]

@rjbernardoMD @SandeepSahayMD @yonsung97 @REstradaMD @RogerAlvarezDO @RFPMachado @heresi_gustavo @sonjabart @mardigomberg @ChaseStroudMD @LungTxptMD I agree with you w.r.t side effects. Seen it in two patients so far but only one had a repeat RHC. Any changes in systemic BP ?

[Rahul G Argula @RahulArgula]

@rjbernardoMD @SandeepSahayMD @yonsung97 @REstradaMD @RogerAlvarezDO @RFPMachado @heresi_gustavo @sonjabart @mardigomberg @ChaseStroudMD @LungTxptMD In the trials, I have had to do it in two patients (2/12 odd patients). So far, I have not had to do it much but these are still early days. Most likely there are going to be super responders to this drug and we will better phenotype them over time.

[Rahul G Argula @RahulArgula]

@RyanTedfordMD @bmprii @kiawahresort That is an acceptable excuse ;)

[Rahul G Argula @RahulArgula]

Had a great conversation about BMPR signal modulation from the guru himself @bmprii . Arguably, the most consequential and paradigm changing work that helps the right ventricles of PAH patients. Wait, where is @RyanTedfordMD ?

[Rahul G Argula @RahulArgula]

Amazing two days at PHA 2024. Felt the energy after connecting with the PH community. I’m so glad that the entire MUSC PVD team (except Denise :( )got to experience PHA this year. MUSC was well represented. Grateful for all the talented and hardworking people that I work with.

[Rahul G Argula @RahulArgula]

@rjbernardoMD @RFPMachado @IUPCCM Congratulations and Good luck @rjbernardoMD

[Rahul G Argula @RahulArgula]

@LucillaPiccari @ThomasGILLE_MD @SaraOcana1 @ErsPvd @LichtblauMD @SandeepSahayMD @leticiakawano @KerriBerriKerri @Katerin27451987 @PullamsettiL @PilarRiveraOrt1 Congratulations! Missed it this year! Will be there next year!

[Rahul G Argula @RahulArgula]

This is one of the best commencement addresses I've seen.

[Vala Afshar @ValaAfshar]

“The kindest person in the room is often the smartest.”

[Rahul G Argula @RahulArgula]

Great study! iNO consumes a significant amount of resources in health systems. Substitution of iNO with iEPO can translate into significant cost savings!

[Jason N. Katz @JasonKatzMD]

Really important study by @KamGhadimiMD and others @DukeHeartCenter. Amazing work. Must read! @ShashankSinhaMD @Carnicelli_Ant @seanvandiepen @RanLeeMD @criticalecho Inhaled Epo vs Nitric Oxide for RV Support After Major Cardiac Surgery | Circulation https://t.co/a8nSZw8uyn

[Rahul G Argula @RahulArgula]

@rjbernardoMD @RFPMachado Congratulations Roberto! Best wishes!

[Rahul G Argula @RahulArgula]

@LucillaPiccari 😂😂 your article clearly cut across traditional academic boundaries....if one ignores the automated email spamming technology behind it, one should wear it like a badge of honor! #PHuelling the awareness!

[Rahul G Argula @RahulArgula]

Great thread! Nice work @DrTimFernandes , @nickhsk_phdoc

[Timothy Fernandes, MD, MPH @DrTimFernandes]

I'm pleased to share this new, important paper from our group @ucsdhealth on distal pulmonary thromboendarterectomy results in #CTEPH. Outcomes were similar for distal (Level 3/4) vs. proximal disease (Level 1/2). 🔑 points in 🧵:

https://t.co/FQXGLNHR03

[Rahul G Argula @RahulArgula]

If you are planning on attending ATS 2023 and have an interest in PH in the SSc patient, don't forget to register for my talk. See below for details. The registrations are limited, on a first come first serve basis (not my rules sorry) so don't wait for the last minute.

[Rahul G Argula @RahulArgula]

Interested in learning about pulmonary hypertension (PH) in Systemic sclerosis (SSc) ? Join me for a talk at #ATS2023 about the complex and overlapping phenotypes of PH in SSc & their Rx using case studies from our multi-disciplinary SSc program at MUSC. https://t.co/EOdy6TQiT5

[Rahul G Argula @RahulArgula]

@RyanTedfordMD @YevgeniyBr @cfbechara @IRajapreyar @HornEvelyn @PForfiaPHDOC @darki_amir @Carnicelli_Ant @Brian_Houston12 💯. For two reasons : The occlusion may not always be complete. More importantly, the acute response post AVF occlusion in the cath lab may not predict the hemodynamic consequences of long term AVF ligation. After all , the PH and heart failure are chronic sequela of the AVF.

[Rahul G Argula @RahulArgula]

@docbhardwaj @JCardFail @ewarnermd @YevgeniyBr @EstefaniaOS @IRajapreyar @robmentz @dranulala @RyanTedfordMD @AHajduczok @DrMarthaGulati @ShelleyZieroth @AndrewJSauer @vbluml On my list to read. This is a highly underrecognized problem. Dyspnea in the ESRD patient is complex. This has implications from a kidney tx work up standpoint as well. I think increasing awareness will start moving the needle!

[Rahul G Argula @RahulArgula]

You will have to register to be able to attend the talk. Session details: MTE49- PHENOTYPING SYSTEMIC SCLEROSIS ASSOCIATED PULMONARY HYPERTENSION

[Rahul G Argula @RahulArgula]

Interested in learning about pulmonary hypertension (PH) in Systemic sclerosis (SSc) ? Join me for a talk at #ATS2023 about the complex and overlapping phenotypes of PH in SSc & their Rx using case studies from our multi-disciplinary SSc program at MUSC. https://t.co/EOdy6TQiT5

[Rahul G Argula @RahulArgula]

@RyanTedfordMD @MUSChealth @PVRI @GiessenPh @phaware @PHAssociation @MarlaChoren @SandeepSahayMD @SamFriedman90 @JournalClubPH @PulmonaryHIndia @dawg_ph @ATS_PC